Jan Rutherford is a principal at SEP, focusing on therapeutics, specialty pharmaceuticals and contract pharmaceutical services. She led SEP’s investment in the contract research organisation Cmed, which is deploying its proprietary Timaeus technology for the electronic capture and management of clinical trial data.
Before joining SEP, Jan was with Dresdner Kleinwort Capital’s Life Science team in London, where she managed investments in biotechnology and medical device companies in Europe and the USA. Jan is a registered pharmacist and her previous background is in drug development and clinical research, working for Quintiles, Merck Sharp & Dohme and Sandoz/Novartis.
